This CDK 4/6inhibitor is the onlyone in its drugclass also used inearly stage breastcancerThis should bemonitoredroutinely every3-4 monthswhile receivingtrastuzumab This agentshould beinitiated withneratinib for thefirst 8 weeks1%Patients withHER2+ diseasecontinuetargetedtherapy for thisdurationI can give thisagent in highrisk BRCA1/2 mutationfor 1 yearThis agent iswell studied fortamoxifeninduced hotflashes inbreast cancerPreferredregimen forHR+ diseasefor frail/elderlypatientsThis agent cancauseendometrialcancer, but hasbone densityprotective effectDuration of timepatients willtakeabemaciclib inearly stagediseaseBased onTAILORx, <50years receivechemoendocrinetherapy if theyhave thisOncotypeDx score This agent is notused inpremenopausalwomen as endocrinetherapy unless theyalso receive ovariansuppression The onlysteroidalaromataseinhibitor in itsdrug classThis prodrug isgiven in TNBC forpatients who do notachieve pathologiccomplete responsebased on CREATE-X trialPreferredfrequencyof GnRHagonistsThe ATLAS,AttOM, MA.17Rtrials evaluatedthis durationbenefit ofendocrine therapyUsed asneoadjuvant andadjuvant therapyin high risk TNBCbased on theKEYNOTE 522trialThis treatmentmodality isalwayscombined withlumpectomysurgeryBased onOncotype DX,a score of 35will receivethis treatmentThis subtype ofbreast cancerhas the lowestrelative 5-yearsurvival rate This agent canbe added toLN+ HER2+disease givenwithtrastuzumabThis drugclass are thebackbone ofHR+ diseaseThis drug class iscontraindicatedcombined withtrastuzumab-avoid for 7 monthsafter lasttrastuzumab dosePatients who donot achieve pCRin HER2+disease and haveresidual diseaseget this therapyThis CDK 4/6inhibitor is the onlyone in its drugclass also used inearly stage breastcancerThis should bemonitoredroutinely every3-4 monthswhile receivingtrastuzumab This agentshould beinitiated withneratinib for thefirst 8 weeks1%Patients withHER2+ diseasecontinuetargetedtherapy for thisdurationI can give thisagent in highrisk BRCA1/2 mutationfor 1 yearThis agent iswell studied fortamoxifeninduced hotflashes inbreast cancerPreferredregimen forHR+ diseasefor frail/elderlypatientsThis agent cancauseendometrialcancer, but hasbone densityprotective effectDuration of timepatients willtakeabemaciclib inearly stagediseaseBased onTAILORx, <50years receivechemoendocrinetherapy if theyhave thisOncotypeDx score This agent is notused inpremenopausalwomen as endocrinetherapy unless theyalso receive ovariansuppression The onlysteroidalaromataseinhibitor in itsdrug classThis prodrug isgiven in TNBC forpatients who do notachieve pathologiccomplete responsebased on CREATE-X trialPreferredfrequencyof GnRHagonistsThe ATLAS,AttOM, MA.17Rtrials evaluatedthis durationbenefit ofendocrine therapyUsed asneoadjuvant andadjuvant therapyin high risk TNBCbased on theKEYNOTE 522trialThis treatmentmodality isalwayscombined withlumpectomysurgeryBased onOncotype DX,a score of 35will receivethis treatmentThis subtype ofbreast cancerhas the lowestrelative 5-yearsurvival rate This agent canbe added toLN+ HER2+disease givenwithtrastuzumabThis drugclass are thebackbone ofHR+ diseaseThis drug class iscontraindicatedcombined withtrastuzumab-avoid for 7 monthsafter lasttrastuzumab dosePatients who donot achieve pCRin HER2+disease and haveresidual diseaseget this therapy

BC questions - Call List

(Print) Use this randomly generated list as your call list when playing the game. There is no need to say the BINGO column name. Place some kind of mark (like an X, a checkmark, a dot, tally mark, etc) on each cell as you announce it, to keep track. You can also cut out each item, place them in a bag and pull words from the bag.


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
  1. This CDK 4/6 inhibitor is the only one in its drug class also used in early stage breast cancer
  2. This should be monitored routinely every 3-4 months while receiving trastuzumab
  3. This agent should be initiated with neratinib for the first 8 weeks
  4. 1%
  5. Patients with HER2+ disease continue targeted therapy for this duration
  6. I can give this agent in high risk BRCA 1/2 mutation for 1 year
  7. This agent is well studied for tamoxifen induced hot flashes in breast cancer
  8. Preferred regimen for HR+ disease for frail/elderly patients
  9. This agent can cause endometrial cancer, but has bone density protective effect
  10. Duration of time patients will take abemaciclib in early stage disease
  11. Based on TAILORx, <50 years receive chemoendocrine therapy if they have this OncotypeDx score
  12. This agent is not used in premenopausal women as endocrine therapy unless they also receive ovarian suppression
  13. The only steroidal aromatase inhibitor in its drug class
  14. This prodrug is given in TNBC for patients who do not achieve pathologic complete response based on CREATE-X trial
  15. Preferred frequency of GnRH agonists
  16. The ATLAS, AttOM, MA.17R trials evaluated this duration benefit of endocrine therapy
  17. Used as neoadjuvant and adjuvant therapy in high risk TNBC based on the KEYNOTE 522 trial
  18. This treatment modality is always combined with lumpectomy surgery
  19. Based on Oncotype DX, a score of 35 will receive this treatment
  20. This subtype of breast cancer has the lowest relative 5-year survival rate
  21. This agent can be added to LN+ HER2+ disease given with trastuzumab
  22. This drug class are the backbone of HR+ disease
  23. This drug class is contraindicated combined with trastuzumab- avoid for 7 months after last trastuzumab dose
  24. Patients who do not achieve pCR in HER2+ disease and have residual disease get this therapy